GlaxoSmithKline (GSK) has announced its acquisition of Rapt Therapeutics for approximately $2.2 billion, marking a significant expansion in its immunology division. This strategic move aims to...
In a significant advancement in cancer treatment, researchers at the Sloan Kettering Institute and Weill Cornell Medical College announced on December 6, 1954 the development of...
GlaxoSmithKline (GSK) has announced a significant leadership transition, appointing Luke Miels as the new Chief Executive Officer, effective January 1, 2024. Miels, who has served as...
